Radius Health

Radius Health ($RDUS)
Based: Waltham, MA
IPO price: $8
Close Sept. 30: $21
Change: Up 163%
Raised: $52 million

Scoop: Radius' IPO is, in terms of postpricing performance, the most successful on this list. In fact, if not for GoPro ($GPRO) and its nearly 300% Wall Street explosion, the patch-focused biotech would have 2014's highest-flying debut in any industry. Unfortunately for Radius, however, timing and market tumult made it so that the primary beneficiaries of its strong performance were investors, not the company's pipeline therapies. Radius unveiled plans for a $92 million IPO back in April, when the previously roiling reception for biotechs had severely tightened up, and by the time the company made it out in June, it managed to price at just $8 a share, 50% below the top of its previous range. But the promise of Radius' pipeline won out eventually, and the company's shares are continuing to rise as it moves toward revealing Phase III results on the subcutaneous abaloparatide, its peptide-based osteoporosis treatment designed to improve bone density. And Radius wasn't completely shut out of its IPO success: Earlier this month, the biotech pulled off a secondary offering that brought in more than $50 million, selling off new shares at 228% of its initial price.

For more:
Biotech's post-boom swoon mars IPO efforts from Radius, Agile
Radius dials up a $92M IPO pitch despite tepid market for biotechs

Radius Health

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.